Currently, one of the main threats to public health is diabetes mellitus. Its most detrimental complication is diabetic nephropathy (DN), a clinical syndrome associated with kidney damage and an increased risk of cardiovascular disease. Irrespective of the type of diabetes, DN follows a well-known temporal course. The earliest detectable signs are microalbuminuria and histopathological changes including extracellular matrix deposition, glomerular basement membrane thickening, glomerular and mesangial expansion. Later on macroalbuminuria appears, followed by a progressive decline in glomerular fi ltration rate and the loss of glomerular podocytes, tubulointerstitial fi brosis, glomerulosclerosis and arteriolar hyalinosis. Tight glycemic and hypertension controls remain the key factors for preventing or arresting the progression of DN. Nevertheless, despite considerable educational eff ort to control the disease, a signifi cant number of patients not only develop DN, but also progress to chronic kidney disease. Therefore, the availability of a strategy aimed to prevent, delay or revert DN would be highly desirable. In this article, we review the pathophysiological features of DN and the therapeutic mechanisms of multipotent mesenchymal stromal cells, also referred to as mesenchymal stem cells (MSCs). The perfect match between them, together with encouraging pre-clinical data available, allow us to support the notion that MSC transplantation is a promising therapeutic strategy to manage DN onset and progression, not only because of the safety of this procedure, but mainly because of the renoprotective potential of MSCs.
According to the World Health Organization, the total number of people with diabetes mellitus (DM) is projected to rise from 285 million in 2010 to 439 million in 2030 (Shaw et al., 2010) . Regarding its etiology, DM is classifi ed as type 1 (T1DM) or type 2 (T2DM). While T1DM is due to autoimmune destruction of pancreatic beta cells leading to insulin defi ciency (Cnop et al., 2005) , T2DM is a metabolic disorder due to insulin resistance along with impaired insulin secretion (Cnop et al., 2005) . Over the past decades, medical advances have substantially improved the management of patients with DM, thereby prolonging their survival (Penfornis et al., 2011) . Nevertheless, available treatments do not guarantee a tight glycemic control, since patients do not often adhere well to medical indications. Thus even under treatment patients develop chronic macro-and microvascular diseases including stroke, neuropathy, retinopathy and nephropathy (Stolar, 2010; Maric and Hall, 2011) . Among these, diabetic nephropathy (DN) is the most detrimental consequence with regard to both premature morbimortality and medical expense s (BlazquezMedela et al., 2010; Stolar, 2010) . Furthermore, DN represents a major concern for public health worldwide, since 25% to 40% of the patients with DM develop it, and also because as DN progresses to end-stage chronic kidney disease, patients require hemodialysis and even kidney transpla nt (McCrary, 2008; Reutens and Atkins, 2011) .
PATHOPHYSIOLOGICAL FEATURES OF DIABETIC NEPHRO-PATHY
DN is a clinical syndrome consisting of kidney damage and increased risk of cardiovascular diseases. Its main risk factors are gender, genetic factors, renal hemodynamics and age of DM onset (Blazquez-Medela et al., 2010) . Although the time of clinical debut of DN varies between patients with T1DM and T2DM, clinical and histological progressions in both conditions are quite similar (Najafi an et al., 2011) . Changes in the fi ltration unit begin soon after DM onset, and take place "silently" for a long time before the appearance of the fi rst clinical signs of the disease. In susceptible patients DN follows a well-known physiopathological course (Figure 1) . Microalbuminuria is the earliest clinically detectable sign of kidney damage. It is associated with histological changes that include extracellular matrix deposition, glomerular basement membrane thickening and glomerular mesangial expansion. In later stages patients develop macroalbuminuria, followed by a progressive decline in the glomerular fi ltration rate. At this stage, histological changes include glomerulosclerosis, tubulointerstitial fi brosis and arteriolar hyalinosis (Najafi an et al., 2011) .
Although hyperglycemia itself is not suffi cient to provoke development of DN, the main promoting factors are the following metabolic and hemodynamic alterations (Figure 1 ): -augmented oxidative stress. High glucose fl ux increases the production of superoxide anions in the mitochondrial electron transport chain (Rolo and Palmeira, 2006) . Excessive production of superoxide anions results in the formation of more superoxide anion and secondary reactive oxygen species (ROS) including peroxynitrite and hydroxyl radicals, which modify DNA, proteins and lipids (Brownlee, 2001) . Along with a deregulation of anti-oxidant enzymes, increased oxidative stress leads to endothelial dam age (Evans et al., 2002) . Furthermore, ROS up-regulate the expression of TGF-beta1, PAI-1 and extracellular matrix (ECM) proteins in glomerular mesangial cells, triggering mesangial expan sion (Fujita et al., 2009 ).
-accumulation of advanced glycation end products and fibrosis. High glucose concentration results in nonenzymatic glycation of proteins, lipids and nucleic acids (Yamagishi and Matsui, 2010) . These advanced glycation end products (AGEs) interact with membrane receptors that induce crosslinking of ECM proteins and slow down their turnover. Thus the normal interactions among ECM proteins are disrupted in a way that compromises their function and leads to fi brosis. Furthermore, aberrant cell-ECM interactions lead to the alteration of cell adhesion, proliferation and epithelial phenotype maintenance, stimulating epithelial-to-mesenchymal trans ition (Simonson, 2007; Yamagishi and Matsui, 2010) . In addition, AGEs induce ROS synthesis and ROS accelerate AGE formation (Singh et al., 2011) . This positive feedback between AGEs and ROS worsens renal tissue damage.
-chronic infl ammation. DN was considered to be a nonimmune disease. Nevertheless, it has been shown recently that inflammation is crucial for the development of microvascular complications of DM, including nephr opathy (Mora and Navarro, 2006; Ortiz-Munoz et al., 2010) .
Accordingly, lymphocytes, monocytes and macrophages have been involved in DN prog ression (Galkina and Ley, 2006; Ninichuk et al., 2007) . Moreover, it has been proved that IL-1beta, IL-6 and TNF-alpha are relevant for the developme nt of DN (Mocan et al., 2006; Mora and Navarro, 2006) . IL-1beta and IL-6 increase vascular endothelial permeability and alter ECM dynamics at both the mesangial and podocyte levels, contributing to interstitial infi ltrates, glomerular basement membrane thickening, mesangial expansion, and tubula r atrophy (Pecoits-Filho et al., 2002; Dalla et al., 2005) . TNF-alpha is cytotoxic to renal cells and contributes to sodium retention and renal hypertrophy, alterations that are observed during the earlier stages of DN (DiPetrillo et al., 2004) . Also, the exposure of tubular epithelial cells to TNF-alpha results in a significant increase in the synthesis and secretion of lymphocyte-and neutrophil-chemoattractant factors, and in the cell surface expression of ICAM-1 (Ishikura et al., 1991) . Accordingly, the up-regulation of MCP-1 and ICAM-1 in the kidney has been associated with macrophage and lymphocyte recruitment, urinary albumin excretion, tubulointerstitial injury and DN progression (Matsui et al., 1996; Chow et al., 2006) . In addition, TNF-alpha directly promotes the local generation of ROS, resulting in the alteration of the function of glomerular capillary barrier wall, which allows the permeatio n of albumin (McCarthy et al., 1998) . AGEs: advanced glycation end products, RAS: renin-angiotensin system, ECM: extracellular matrix, GBM: glomerular basement membrane.
-altered renin-angiotensin system. Angiotensin II shows increased activity during DN, and causes hypertrophy of mesangial and tubular epithelial cells (Chawla et al., 2010) . Also, it has pressor eff ects on arteriolar smooth muscle, increasing vascular pressure. Furthermore, Angiotensin II induces inflammation, apoptosis and promotes the production of TGF-beta and MCP-1, two prosclerotic cytokines that have been identified as responsible for glomerular sclerosis.
-steatosis and atherosclerosis. Patients with T2DM present additional factors that aggravate renal damage, i.e. obesity, dyslipidemia, atherosclerosis that results in renal ischemia and hypertension (Maric and Hall, 2011; Packham et al., 2011) . Lipid deposition in the kidneys produces direct glomerular injury, and may also result in glomerular mesangial cell activation and proliferation (Wang et al., 2005) . Activation of these cells leads to chemokine production, which promotes the recruitment of monocytes and their maturation into macrophages in the mesangium. Furthermore, it has been shown that renal mesangial and tubular cells grown in culture and incubated with LDL or VLDL up-regulate the expression of TGF-beta and PAI-1 and accumulate ECM proteins (Vaziri and Norris, 2011), thus demonstrating that lipids have a direct role in the activation of glomerulosclerosis mediators.
AVAILABLE STRATEGIES TO MANAGE PATIENTS WITH DIA-BETIC NEPHROPATHY
There is currently no cure for patients with DN. Palliative therapeutic strategies include the use of drugs to control hyperglycemia, blood pressure and proteinuria (Yamagishi et al., 2007; Choudhury et al., 2010) . In advanced stages patients receive renal replacement therapy, which consists of hemodialysis and, if possible, kidney transplantation (Reutens and Atkins, 2011). Unfortunately, the latter is only useful when the kidney is co-transplanted with pancreatic beta-islets; if this is not done, renal failure reappears (Fioretto and Mauer, 2012) . Therefore, the need for therapeutic strategies to prevent, delay or revert DN is compelling.
STEM CELL-BASED STRATEGIES TO MANAGE PATIENTS WITH DIABETIC NEPHROPATHY
Pharmacological interventions often target only a single pathophysiological feature of the disease, e.g. the inhibitors of the renin-angiotensin system used for the management of patients with DN suppress urinary albumin excretion in a relatively short term but do not prevent renal function decline and the progression to end-stage chronic kidney disease (Jerums et al., 2008) . Conversely, stem cell-based intervention is known to act through multiple mechanisms, a clear advantage when facing diseases with highly complex pathophysiology, as is the case of DN. Choosing the adequate stem cell for this purpose should take into account the following notions:
-embryonic stem cells are obtained from the inner cell mass of a blastocyst and are pluripotent; i.e., they can give rise to endo-, meso-and ectodermal cells. Their teratogenicity raises a major concern regarding biosafety. Bioethical, religious and political issues have limited the studies aimed to evaluate their putative massive therapeutic use (Mertes and Pennings, 2009 ).
-induced pluripotent stem cells are generated after somatic ce ll reprogramming (Takahashi et al., 2007) . These cells are pluripotent and teratogenic, thus they share the biosafety concerns with embryonic stem cells. To avoid this problem, researchers have proposed that pluripotent stem cells should be fi rst diff erentiated in vitro and then transplanted. This imposes at least two major technical problems to solve; the defi nition of proper and effi cient diff erentiation conditions, and the development of procedures for the delivery of diff erentiated cells into damaged tissues.
-adult stem cells are found in all non-embryonic tissues; hence they may be isolated from fetus, newborn, child and adult individuals. They contribute to both maintenance of cellular homeostasis and regeneration of damaged organs. Adult stem cells are multipotent, and due to their limited self-renewal potential, not teratogenic. Some of them also have plasticity, i.e., they can diff erentiate into cells from lineages diff erent from their origin (Phinney and Prockop, 2007) .
Since adult stem cells pose less bioethical and technical concerns, the fi rst candidate for a stem cell-based strategy to treat DN was bone marrow-derived stem cells. Bone marrow harbors at least two distinct adult stem cells; the hematopoietic stem cells that give rise to blood and endothelial cells (Wagers and Weissman, 2004 ) and the multipotent mesenchymal stromal cells, also referred to as mesenchymal stem cells (MSCs), that give rise to adipocytes, chondrocytes, o steocytes and myocytes (Minguell et al., 2001; Dominici et al., 2006) . Additionally, it has been suggested that MSCs might cross the germ line barrier and generate cells from the endo-and ectodermal lineages (Phinney and Prockop, 2007) .
The main advantage of MSCs over hematopoietic stem cells for clinical use is their hypoimmunogenicity, since histocompatibility between donor and receptor is not required. Also, recipients do not need to be conditioned before MSC transplantation, as is the case in total bone marrow or hematopoietic stem cell transplantation (Uccelli et al., 2008) . Furthermore, it is currently agreed that MSCs contribute to tissue regeneration not only because of their diff erentiation potential, but also because of the following therapeutic mechanisms (Figure 2 ): -scavenging of oxidative stress. MSCs are highly resistant to ex vivo culture and ionizing radiation, which are two conditions that generate strong oxidative stress. Recently we demonstrated that the low susceptibility of MSCs to the deleterious eff ect of ROS and reactive nitrogen species correlates with the ability of these cells to eff ectively scavenge peroxide and peroxynitrite, due to the constitutive expression of SOD1, SOD2, CAT and GPX1 enzymes and high levels of glutathione (Valle-Prieto and Conget, 2010). Moreover, MSCs possess the main enzymatic mechanisms to detoxify reactive species and to prevent oxidative damage of the proteome and genome (Salmon et al., 2009 ). Thus, MSCs are endowed with the main molecular mechanisms to manage oxidative stress effi ciently.
-anti-fi brosis. The role of MSCs in fi brosis is still a matter of controversy. Some studies have indicated that MSCs have no eff ect, others show an increase and others show a decrease (Carvalho et al., 2008; di Bonzo et al., 2008; Ezquer et al., 2011) . These diff erences may be related, at least in part, to the characteristics of target tissues, fi brosis etiology, the stage of disease at the moment of MSC administration and follow up time. The anti-fi brosis eff ect of MSCs could be direct, i.e. through the regulation of ECM protein synthesis and degradation, or indirect, i.e. due to the preclusion of leukocyte infi ltration and/or the inhibition of pro-fi b rotic cytokine secretion (Higashiyama et al., 2007; Semedo et al., 2009a ).
-immunomodulation. MSCs express constitutively major histocompatibility complex class I, and after induction major histocompatibility complex class II (Rasmusson, 2006) . However, they do not present in the cell surface costimulatory molecules such as B7-1, B7-2, CD40 y CD40L. Hence, they activate neither allogeneic lymphocytes nor a proliferative response in helper CD4+ T lymphocytes, and they are not targeted by CD8 + cytotoxic T lymphocytes (Tse et al., 2003) . Furthermore, MSCs are capable of inhibiting the diff erentiation of monocyte precursors into activating dendritic cells, and of altering the function of mature dendritic cells . Thus MSCs indirectly limit the cytotoxic expansion and activity of NK cells and T lymphocytes. And last but not least, MSCs promote the appearance of regulatory T lymphocytes, inducing antigenspecifi c tolerance (Maccario et al., 2005) . MSCs reduce the serum levels of IL-5, IL-12(p40) and TNF-alpha, resulting in a reduction of leukocyte infi lt ration into damaged tissues Semedo et al., 2009b) . In addition, MSC administration leads to modulation of the infl ammation through down-regulation of the Th1 cytokines (IL-1beta, IL-6, IL-12, TNF-alpha and INF-gamma), and up-regulation of Th2 cytokines (IL-4 and IL-10) (Semedo et al., 2009b ).
-secretion of trophic factors. It is known that MSCs have the ability to secrete in vivo and in vitro a wide range of trophic factors, including VEGF, bFGF, PDGF, IGF-1, HGF and EGF (Caplan and Dennis, 2006) . The biological eff ect of these factors can be both direct, i.e. triggering intracellular signalling in the target cell, or indirect, i.e. inducing neighbor cells to secrete bioactive factors. Therefore it has been proposed that MSCs have a catalytic role in tissue regeneration, since once in the damaged tissue they are able to modify the microenvironment by secreting factors that would: (i) prevent parenchymal cells from dying; e.g. anti-apoptotic factors such as HGF and IGF, in models of myocardial infarc tion and acute renal failure (Nigam and Lieberthal, 2000; Kinnaird et al., 2004b) ; (ii) induce the proliferation and diff erentiation of endogenous progenitors; e.g. neurogenic factors such as NGF and BDNF, in models of neuronal damage (Neuhuber et al., 2005) ; (iii) promote neovascularization; e.g. angiogenic and vasculogenic factors such as VEGF and bFGF, in models of acute myocardial infarction an d ischemic acute renal failure (Kinnaird et al,. 2004a; Togel et al., 2007) .
MSC TRANSPLANTATION: A PROMISING STRATEGY TO MA-NAGE PATIENTS WITH DIABETIC NEPHROPATHY General support
Although MSCs are scarce (less than 0.01% in the bone marrow), they appear as ideal candidates to prevent, delay or revert DN, since (i) they can be obtained from donors without major complications; (ii) they can be expanded ex vivo; (iii) they are hypoimmunogenic; (iv) once administered intravenously, they are able to home into damaged organs where they may protect the parenchyma from noxa, organize endogenous In damaged kidney, they will cross the endothelium, home into the parenchyma and migrate to the injured areas. MSCs will contribute to renal tissue regeneration through, at least, one of the mechanisms shown in the fi gure. ROS: reactive oxygen species, RNS: reactive nitrogen species, APC: antigen presenting cell. 
Indirect support
Indirect support for the putative contribution of donor MSC to the management of individuals with DN includes: (i) recipient MSCs play a key role in normal turnover and remodeling of renal structures including renal vessels, interstitial myofibroblast cells, glomerular mesang ium, podocytes and tubular epithelium (Cornacchia et al., 2001; Grimm et al., 2001; Poulsom et al. 2001; Gupta et al., 2002) ; (ii) in mice models of Alport syndrome and glomerulonephropathy, MSC administr ation results in clinical improvements (Sugimoto et al., 2006; Wong et al., 2008) ; (iii) in rodent models of acute tubular epithelial injury and experimental glomerulonephritis, donor MSCs contribute to the functional and structural recovery of b oth glomerular and tubular compartments (Morigi et al., 2004; Krause and Cantley, 2005; Qian et al., 2008) ; (iv) in rat remnant kidney models, MSC transplantation attenuates renal fi brosis and pro duces a reduced glomerulosclerosis index (Semedo et al., 2009a) . This was correlated with a reduction in the expression of pro-fi brotic molecules such as collagen type I, collagen type III, fi bronectin, vimentin, ASMA, FSP-1 and TGF-beta. It was also associated with a change of the ratio between MMP-9 and TIMP-1, indicative of recovery in the balance between synthesis and degradation of ECM components; (v) in animal models of acute kidney injury MSC transplantation was benefi cial . It was also observed that IGF-1 produced by MSCs reduces apoptosis and increases cell proliferation of the proximal tubular epithelium, whereas HGF secreted by MSCs enhanc es the remodeling of fi brotic renal tissue (Imberti et al., 2007) ; (vi) ongoing clinical trials are assessing the safety and effi cacy of MSCs to treat cisplastininduced acute renal failure and lupus nephritis (Giordano et al., 2007; www.clinicaltrials.gov) .
Direct support
To our knowledge, there are only four published reports showing, at the pre-clinical level, that MSC-based therapy could be useful for the prevention or the reversion of renal failure in diabetic individuals. In an immunodefi cient nonobese diabetic mouse model, it has been shown that after the intracardiac injection of a large number of human MSCs (≈250x10 6 /kg body weight) , few donor cells were found in the kidneys (Lee et al., 2006) . Unfortunately, it is not known whether this had any functional consequence, as animals did not present renal failure before the intervention or during the follow-up period. In mice with T1DM induced by the administration of fi ve low doses of streptozotocin, we showed that the intravenous administration of syngeneic MSCs (≈20x10 6 /kg body weight) results in the reduction of microalbuminuria an d the preservation of normal renal histology (Ezquer et al., 2008) . By contrast, untreated diabetic mice remained albuminuric and presented glomerular hyalinosis and mesangial expansion. In rats with diabetes induced by the administration of a single high dose of streptozotocin, the intracardiac infusion of allogeneic MSCs (≈10x10 6 /kg body weight) along with cyclosporine resulted in a transient amelioration of renal function and structure (Zhou et al., 2009 ). In the latter two reports, after MSC administration an improvement in the diabetes condition was also observed. To determine whether the renoprotective eff ect of MSCs is indirect, i.e. due to hyperglycemia correction, or direct, i.e. due to protection/regeneration of renal tissue, we administered syngeneic MSCs in a mouse model that develops severe diabetes after the in fusion of a single high dose of streptozotocin (Ezquer et al., 2009) . Despite not sharing the etiology of either T1DM or T2DM, these animals showed a rapid progression of renal failure and developed most of the pathognomonic signs of DN. In these diabetic mice, MSC administration did not result in hyperglycemia correction; however, renal failure did not progress. In contrast, in untreated diabetic mice microalbuminuria gradually increased and renal histopathological alterations were evident at the end of the study period. Interestingly, at least up to three months after MSC administration donor cells were found in the kidney of severe diabetic mice. None of the published reports explored the mechanisms behind renoprotection. But, due to the scarce numbers of donor cells found in recipient kidneys, it is expected that mechanisms diff erent than cell diff erentiation will be relevant.
Potential limitations to clinical translation
Data supporting the contribution of donor MSCs to the management of renal failure in diabetic individuals have been generated in the available animal models of DN. Unfortunately, those model s only reproduce the earlier stages of human DN (Breyer et al., 2005; Inada et al., 2005; Alpers and Hudkins, 2011) . Non-obese and streptozotocin-induced diabetic mice progress to proteinuria and hyperfi ltration. They also present variable degrees of mesangial matrix expansion and glomerular capillary basement membrane thickening, but infrequently develop nodular glomerulosclerosis, a pathognomonic sign of advanced human DN. Hence the impact of MSC transplantation in individuals with advanced DN remains unproved. No dose-response studies have been performed, since the optimal dose of MSCs is unknown. Also, the cellular and molecular mechanisms behind MSC renoprotection in a diabetic environment are still unidentifi ed. Thus more preclinical and clinical trials should be designed and performed in order to assess the safety and effi cacy of MSC transplantation in individuals with DN.
CONCLUSION
The perfect match between the pathophysiological features of DN and the therapeutic mechanisms of MSCs, together with the encouraging pre-clinical data available supports the notion that MSC transplantation is a promising therapeutic strategy to manage DN onset and progression, not only because of the safety of this procedure, but mainly because of the renoprotective potential of MSCs.
